3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines: CCK-A agonists that demonstrate oral activity as satiety agents.
Henke
B R
BR
Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina 27709, USA. henkebr@glaxo.com
Willson
T M
TM
Sugg
E E
EE
Croom
D K
DK
Dougherty
R W
RW
Queen
K L
KL
Birkemo
L S
LS
Ervin
G N
GN
Grizzle
M K
MK
Johnson
M F
MF
James
M K
MK
D000284:Administration, Oral; D000818:Animals; D001569:Benzodiazepines / Q000737:chemistry / Q000494:pharmacology*; D001665:Binding Sites; D016466:CHO Cells; D002766:Cholecystokinin / Q000819:agonists*; D006224:Cricetinae; D005704:Gallbladder / Q000187:drug effects; D006168:Guinea Pigs; D006801:Humans; D051379:Mice; D012528:Satiety Response / Q000187:drug effects*; D013329:Structure-Activity Relationship
D001569:Benzodiazepines; D002766:Cholecystokinin